Adjuvant therapy in esophagogastric adenocarcinoma: Controversies and consensus

Gastrointestinal Cancer Research

Volumn 5, Issue 3, 2012, Pages 85-92

  Ku, Geoffrey Y ^a   Ilson, David H ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; CAPECITABINE; CARBOPLATIN; CETUXIMAB; CISPLATIN; EPIRUBICIN; ERLOTINIB; ETOPOSIDE; FLUOROURACIL; FOLINIC ACID; GIMERACIL PLUS OTERACIL POTASSIUM PLUS TEGAFUR; OXALIPLATIN; PACLITAXEL; TRASTUZUMAB;

ADD ON THERAPY; CANCER ADJUVANT THERAPY; CANCER RADIOTHERAPY; CANCER SURVIVAL; CHEMORADIOTHERAPY; CONSENSUS DEVELOPMENT; ESOPHAGEAL ADENOCARCINOMA; ESOPHAGUS CANCER; ESOPHAGUS SURGERY; HUMAN; INTERMETHOD COMPARISON; MOLECULARLY TARGETED THERAPY; MULTIPLE CYCLE TREATMENT; PERIOPERATIVE PERIOD; POSITRON EMISSION TOMOGRAPHY; PREOPERATIVE TREATMENT; REVIEW; STOMACH ADENOCARCINOMA; STOMACH CANCER; TREATMENT OUTCOME; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT;

EID: 84867889593     PISSN: 19347820     EISSN: 19347987     Source Type: Journal    
DOI: None     Document Type: Review

References (39)

1. Siegel R, Naishadham D, Jemal A: Cancer statistics, 2012. CA Cancer J Clin 62:10-29, 2012
2. Crew KD, Neugut Ah Epidemiology of upper gastrointestinal malignancies. Semin Oncol 31: 450-464, 2004
3. Devesa SS, Fraumeni JF, Jr: The rising incidence of gastric cardia cancer. J Natl Cancer Inst 91:747-749, 1999
4. Kattan MW, Karpeh MS, Mazumdar M, Bren-nan MF: Postoperative nomogram for disease-specific survival after an RO resection for gastric carcinoma. J Clin Oncol 21:3647-3650, 2003
5. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM: Estimates of worldwide burden of cancer in 2008: GhOBOCAN 2008. IntJ Cancer 127:2893-2917, 2010
6. Macdonald JS: Gastric cancer: Nagoya is not New York. J Clin Oncol 29:4348-4350, 2011
7. Macdonald JS, Smalley SR, Benedetti J, et al. Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. N EnglJ Med 345:725-730, 2001
8. Fuchs C, Tepper J, Niedzwiecki D, et al. Postoperative adjuvant chemoradiation for gastric or gastroesophageal junction (GEJ) adenocarcinoma using epirubicin, cisplatin, and infusiona (Cl) 5-FU (ECF) before and after Cl 5-FU and radiotherapy (CRT) compared with bolus 5-FU/hV before and after CRT: intergroup trial CAhGB 80101. J Clin Oncol 29:725-4003, 2011
9. Hee J, Him DH, Kim S, et al. Phase III trial comparing capecitabine plus cisplatin versus capecitabine plus cisplatin with concurrent capecitabine radiotherapy in completely resected gastric cancer with D2 lymph node dissection: the ARTIST trial. J Clin Oncol 30:268-273, 2012
10. Sakuramoto S, Sasako M, Yamaguchi T, et al. Adjuvant chemotherapy for gastric cancer with S-l, an oral fluoropyrimidine. N Engl J Med 357:1810-1820, 2007
11. Sasako M, Sakuramoto S, Katai H, et al. Five-year outcomes of a randomized phase III trial comparing adjuvant chemotherapy with S-l versus surgery alone in stage II or III gastric cancer. J Clin Oncol 29:4387-4393, 2011
12. Bang YJ, Kim YW, Yang HK, et al. Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (ChASSIC): a phase 3 open-label, randomised controlled trial. Lancet 379:315-321,2012
13. Bonenkamp JJ, Hermans J, Sasako M, et al. Extended lymph-node dissection for gastric cancer. N Engl J Med 340:908-914, 1999
14. Strong VE, Song KY, Park CH, et al. Comparison of gastric cancer survival following RO resection in the United States and Korea using an internationally validated nomogram. Ann Surg 251: 640-646, 2010
15. Cunningham D, Allum WH, Stenning SP, et al. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med 355:11-20, 2006
16. Ychou M, Boige V, Pignon JP, et al. Perioperative chemotherapy compared with surgery alone for resectable gastroesophageal adenocarcinoma: an FNChCC and FFCD multicenter phase III trial. J Clin Oncol 29:1715-1721, 2011
17. Kelsen DP, Ginsberg R, Pajak TF, et al. Chemotherapy followed by surgery compared with surgery alone for localized esophageal cancer. N EnglJ Med 339:1979-1984, 1998
18. Allum WH, Stenning SP, Bancewicz J, Clark PI, Langley RE: hong-term results of a randomized trial of surgery with or without preoperative chemotherapy in esophageal cancer. J Clin Oncol 27:5062-5067, 2009
19. Schuhmacher C, Gretschel S, hordick F, et al. Neoadjuvant chemotherapy compared with surgery alone for locally advanced cancer of the stomach and cardia: European Organisation for Research and Treatment of Cancer randomized trial 40954. J Clin Oncol 28: 5210-5218, 2010
20. Sjoquist KM, Burmeister BH, Smithers BM, et al: Survival after neoadjuvant chemotherapy or chemoradiotherapy for resectable oesopha-geal carcinoma: an updated meta-analysis. Lancet Oncol 12:681-692, 2011
21. Messager M, hefevre JH, Pichot-Delahaye V, Souadka A, Piessen G, Mariette C: The impact of perioperative chemotherapy on survival in patients with gastric signet ring cell adenocarcinoma: a multicenter comparative study. Ann Surg 254:684-693, discussion 693, 2011
22. Bosset JF, Gignoux M, Triboulet JP, et al. Chemoradiotherapy followed by surgery compared with surgery alone in squamous-cell cancer of the esophagus. N Engl J Med 337:161-167, 1997
23. Burmeister BH, Smithers BM, Gebski V, et al. Surgery alone versus chemoradiotherapy followed by surgery for resectable cancer of the oesophagus: a randomised controlled phase II trial. Lancet Oncol 6:659-668, 2005
24. Tepper J, Krasna MJ, Niedzwiecki D, et al: Phase III trial of trimodality therapy with cisplatin, fluorouracil, radiotherapy, and surgery compared with surgery alone for esophageal cancer: CAhGB 9781. J Clin Oncol 26:1086-1092, 2008
25. Urba SG, Orringer MB, Turrisi A, lannettoni M, Forastiere A, Strawderman M: Randomized trial of preoperative chemoradiation versus surgery alone in patients with locoregiona esophageal carcinoma. J Clin Oncol 19:305-313, 2001
26. Walsh TN, Noonan N, Hollywood D, Kelly A, Keeling N, Hennessy TP: A comparison of mul-timodal therapy and surgery for esophageal adenocarcinoma. N Engl J Med 335:462-467, 1996
27. Gaast A, van Hagen P, Hulshof M, et al. Effect of preoperative concurrent chemoradiotherapy on survival of patients with resectable esophageal or esophagogastric junction cancer: Results from a multicenter randomized phase III study. J Clin Oncol 28:462-4004, 2010
28. Stahl M, Walz MK, Stuschke M, et al. Phase III comparison of preoperative chemotherapy compared with chemoradiotherapy in patients with locally advanced adenocarcinoma of the esophagogastric junction. J Clin Oncol 27:851-856, 2009
29. Downey RJ, Akhurst T, llson D, et al. Whole body 18FDG-PET and the response of esophageal cancer to induction therapy: results of a prospective trial. J Clin Oncol 21:428-432, 2003
30. Flamen P, Van Cutsem E, herut A, et al. Positron emission tomography for assessment of the response to induction radiochemotherapy in locally advanced oesophageal cancer. Ann Oncol 13:361-368, 2002
31. Ott K, Weber WA, hordick F, et al: Metabolic maging predicts response, survival, and recurrence in adenocarcinomas of the esophagogastric junction. J Clin Oncol 24:4692-4698, 2006
32. Weber WA, Ott K, Becker K, et al. Prediction of response to preoperative chemotherapy in adenocarcinomas of the esophagogastric junction by metabolic imaging. J Clin Oncol 19:3058-3065, 2001
33. Hordick F, Ott K, Krause BJ, et al: PET to assess early metabolic response and to guide treatment of adenocarcinoma of the oesophagogastric junction: the MUNICON phase II trial. Lancet Oncol 8:797-805, 2007
34. zum Buschenfelde CM, Herrmann K, Schuster T, et al: (18)F-FDG PET-guided salvage neoadjuvant radiochemotherapy of adenocarcinoma of the esophagogastric junction: the MUNICON II trial. J NuclMed 52:1189-1196, 2011
35. Llson DH, Minsky BD, Ku GY, et al: Phase 2 trial of induction and concurrent chemoradiotherapy with weekly irinotecan and cisplatin followed by surgery for esophageal cancer. Cancer 2011 dohl0.1002/cncr.26591. [Epub ahead of print]
36. Bang YJ, Van Cutsem E, Feyereislova A, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oe-sophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet 376:687-697, 2010
37. Ilson D, Goodman K, Janjigian Y, et al: Phase II trial of bevacizumab, irinotecan, cisplatin, and radiation as preoperative therapy in esophageal adenocarci-noma. J Clin Oncol 30:687-697, 2012
38. Meluch A, Bendell J, Peyton J, et al. A phase II trial of preoperative chemoradiation therapy plus bevacizumab and erlotinib in the treatment of localized esophageal cancer. J Clin Oncol 28:687-4108, 2010
39. Medical Research Council Oesophageal Cancer Working Group: Surgical resection with or without preoperative chemotherapy in oesophagea cancer: a randomised controlled trial. Lancet 359:1727-1733, 2002